Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Sets FY 2021 User Fees, With Coronavirus (Somewhat) In Mind

Executive Summary

ANDA submission rate increases, while the NDA and BLA fee drops and the biosimilar fee is unchanged.

You may also be interested in...



PDUFA VII: FDA, Industry Agree To Set Minimum Carryover Balance Levels

The minimum total will increase from eight weeks of operating expenses in FY 2023 to 10 weeks by FY 2025.

As Pandemic Delays Reduce PDUFA Revenues, US FDA Slows Fee-Related Spending

Agency cites “unexpected and large drop in collections” in slashing user-fee-setting contract.

FY 2019 Drug Development Drives FY 2021 User Fees Lower

Biosimilar development programs also are expected to increase, a promising sign for the growing sector, but those fees remained unchanged.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS142656

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel